Company that helps speed drug approvals raises $27 million
Manhattan-based health technology company Aetion has added $27 million to its previously announced Series B round, bringing the total raised in the round to $63 million and the company’s total funding to $77 million. The company attracted strategic investment from Sanofi, UCB, McKesson Ventures, and Horizon Health Services, who join earlier investors including Amgen Ventures. “The expansion of our Series B round was in response to a high degree of unsolicited interest among clients and potential partners that have seen the value we provide first hand,”...